
Ustekinumab in adolescent patients age 12 to 17Â years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Keywords: منطقه پسوریازیس و شاخص شدت; adolescent; biologic; children; pediatric; psoriasis; systemic therapy; ustekinumab; AE; adverse event; CDLQI; Children's Dermatology Life Quality Index; HRQoL; health-related quality of life; HSD; half-standard dose; PASI; Psoriasis Area and Severity Ind